

Highlights of This Issue 6367

SPECIAL FEATURES

CCR Translations

- 6369 **Therapeutic Oligonucleotides: The Road Not Taken**
Cy A. Stein and Sanjay Goel
See commentary p. 6582

Molecular Pathways

- 6373 **The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression**
Benjamin D. Hedley, Alison L. Allan, and Anargyros Xenocostas
- 6381 **TLX1-Induced T-cell Acute Lymphoblastic Leukemia**
Kim De Keersmaecker and Adolfo A. Ferrando

CCR Focus

- 6388 **Antibody Conjugates: The Future Is Now**
Susan E. Bates
- 6389 **Antibody Conjugate Therapeutics: Challenges and Potential**
Beverly A. Teicher and Ravi V.J. Chari
- 6398 **Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox**
Robert J. Kreitman and Ira Pastan
- 6406 **Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends**
Martina Steiner and Dario Neri
- 6417 **Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin**
Alejandro D. Ricart
- 6428 **Brentuximab Vedotin (SGN-35)**
Jessica Katz, John E. Janik, and Anas Younes

- 6437 **Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer**

Patricia M. LoRusso, Denise Weiss, Ellie Guardino, Sandhya Girish, and Mark X. Sliwkowski

- 6448 **SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies**

Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz, and John M. Lambert

Review

- 6459 **Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC**
René H. Medema, Chia-Chi Lin, and James Chih-Hsin Yang

CANCER THERAPY: PRECLINICAL

- 6467 **Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism**
Christopher G. Twitty, Shawn M. Jensen, Hong-Ming Hu, and Bernard A. Fox
- 6482 **Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer**
Ning Jin, Tianyun Jiang, David M. Rosen, Barry D. Nelkin, and Douglas W. Ball
- 6490 **The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization**
Konjeti R. Sekhar, Yerramreddy Thirupathi Reddy, Penthala Narsimha Reddy, Peter A. Crooks, Amudhan Venkateswaran, William Hayes McDonald, Ling Geng, Soumya Sasi, Robert P. Van Der Waal, Joseph L. Roti Roti, Kenneth J. Salleng, Girish Rachakonda, and Michael L. Freeman

6500 **Significant Biological Role of Sp1 Transactivation in Multiple Myeloma**

Mariateresa Fulciniti, Samir Amin, Puru Nanjappa, Scott Rodig, Rao Prabhala, Cheng Li, Stephane Minvielle, Yu-tzu Tai, Pierfrancesco Tassone, Herve Avet-Loiseau, Teru Hideshima, Kenneth C. Anderson, and Nikhil C. Munshi

6510 **Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells**

Jennifer Selever, Guowei Gu, Michael T. Lewis, Amanda Beyer, Matthew H. Herynk, Kyle R. Covington, Anna Tsimelzon, Gabriela Dontu, Patrick Provost, Attilio Di Pietro, Aheène Boumendjel, Kathy Albain, Lucio Miele, Heidi Weiss, Ines Barone, Sebastiano Ando, and Suzanne A. W. Fuqua

6522 **EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies**

Virginie Poindessous, Djamilia Ouaret, Karima El Ouadrani, Aude Battistella, Virginie F. Mégalophonos, Nyam Kamsu-Kom, Amélie Petitprez, Alexandre E. Escargueil, Pascaline Boudou, Sylvie Dumont, Pascale Cervera, Jean-François Fléjou, Thierry André, Christophe Tournigand, Benoist Chibaudel, Aimery de Gramont, and Annette K. Larsen

6531 **Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers**

Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Teresa Gelardi, Sudhir Agrawal, Federica Di Nicolantonio, Aldo Scarpa, Alberto Bardelli, and Giampaolo Tortora

IMAGING, DIAGNOSIS, PROGNOSIS

6542 **High XRCC1 Protein Expression Is Associated with Poorer Survival in Patients with Head and Neck Squamous Cell Carcinoma**

Mei-Kim Ang, Mihir R. Patel, Xiao-Ying Yin, Sneha Sundaram, Karen Fritchie, Ni Zhao, Yufeng Liu, Alex J. Freemerman, Matthew D. Wilkerson, Vonn Walter, Mark C. Weissler, William W. Shockley, Marion E. Couch, Adam M. Zanation, Trevor Hackman, Bhishamjit S. Chera, Stephen L. Harris, C. Ryan Miller, Leigh B. Thorne, Michele C. Hayward, William K. Funkhouser, Andrew F. Olshan, Carol G. Shores, Liza Makowski, and D. Neil Hayes

6553 **Discriminant Analysis of ¹⁸F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma**

Mirwais Wardak, Christiaan Schiepers, Magnus Dahlbom, Timothy Cloughesy, Wei Chen, Nagichettiar Satyamurthy, Johannes Czernin, Michael E. Phelps, and Sung-Cheng Huang

6563 **PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients**

Tamara L. Lotan, Bora Gurel, Siobhan Sutcliffe, David Esopi, Wennuan Liu, Jianfeng Xu, Jessica L. Hicks, Ben H. Park, Elizabeth Humphreys, Alan W. Partin, Misop Han, George J. Netto, William B. Isaacs, and Angelo M. De Marzo

CANCER THERAPY: CLINICAL

6574 **Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin**

Ahmad A. Tarhini, Paul Frankel, Kim A. Margolin, Scott Christensen, Christopher Ruel, Janice Shipe-Spotloe, David R. Gandara, Alice Chen, and John M. Kirkwood

6582 **A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer**

David S. Hong, Razelle Kurzrock, Yun Oh, Jennifer Wheeler, Aung Naing, Les Brail, Sophie Callies, Valérie André, Sunil K. Kadam, Aejaz Nasir, Timothy R. Holzer, Funda Meric-Bernstam, Mayer Fishman, and George Simon
See article p. 6369

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

6592 **Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials**

Ming-Wen An, Sumithra J. Mandrekar, Megan E. Branda, Shauna L. Hillman, Alex A. Adjei, Henry C. Pitot, Richard M. Goldberg, and Daniel J. Sargent

LETTERS TO THE EDITOR

6600

***KRAS* rs61764370 in Epithelial Ovarian Cancer—Letter**

Joanne B. Weidhaas and Frank J. Slack


6601

***KRAS* rs61764370 in Epithelial Ovarian Cancer—Response**

Harvey A. Risch, Andrew Berchuck, and Paul D.P. Pharoah; for the Ovarian Cancer Association Consortium

ABOUT THE COVER

The work by Poindessous and colleagues shows that inhibition of EGFR- and VEGF(R)-signaling by combinations of two small molecule tyrosine kinase inhibitors (TKI), afatinib and vargatef, has synergistic activity in colorectal cancer models that are refractory to combinations of the monoclonal antibodies cetuximab and bevacizumab. Importantly, only the TKIs were able to attenuate the phosphorylation of intracellular EGFR- and VEGFR-receptors which was accompanied by the induction of apoptotic cell death as indicated by TUNEL staining (nuclear DNA in blue, apoptotic nuclei in white). This work provides a rationale for clinical trials of the afatinib and vargatef combination, even in patients with mutant *KRAS*. For details, see the article by Poindessous and colleagues on page 6522 of this issue.



Clinical Cancer Research

17 (20)

Clin Cancer Res 2011;17:6367-6601.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/17/20>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/17/20>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.